Devyser launches Genomic Blood Typing assay: All blood groups, one simple test
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
One severe complication following solid organ transplantation is antibody- and/or cell-mediated rejections of the graft. Early detection of rejection may therefore be of paramount importance to improve graft survival following solid organ transplantation. The present study was conducted to determine the monitoring capability and clinical utility of the Devyser assay designed for the sensitive detection of dd-cfDNA (donor-derived cell-free DNA) in patients following kidney transplantation.
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
Read More
Devyser, a pioneer in advanced genetic testing solutions, proudly announces the global launch of...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a significant...
Read More
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation...
Read More